Chat with Filing

Ask questions about this document

Please log in or register to use the chat feature. Please register first.

RNS - Directorate Change

Company: NUFORMIX PLC Date: 2021-02-10 Language: English

You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:

Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon

 National Storage Mechanism | Additional information  ![](https://tracker.live.rns-distribution.com/track.live-rns/3873719_abef74e1e81917cf8d441a20d8c6f0ac.png)

RNS Number : 5392O

Nuformix PLC

10 February 2021

Nuformix plc

("Nuformix", the "Company" or the "Group")

Directorate Change

Cambridge, UK - 10 February 2021: Nuformix plc (LSE:NFX), announces that Dr Chris Blackwell has resigned as Non-Executive Chairman and Director of the Company with immediate effect due to personal reasons that require his immediate attention.

A process to appoint a new Non-Executive Chairman will start immediately.

Dr Anne Brindley, CEO of Nuformix, said: "Along with the rest of the Board, I would like to thank Chris for his contribution to the Company and we give him our very best wishes. I have enjoyed working closely with Chris and I am excited about driving the business forward with the significant value and opportunity that is in the existing pipeline.  I look forward to being able to communicate in more detail the Company's plans and strategic priorities and our approach to create value for shareholders, in the coming weeks."

Enquiries:

|     |     |
| --- | --- |
| Nuformix plc<br><br>Dr Anne Brindley, CEO<br><br>Fleur Wood, Investor Relations<br><br>Email: fleur.wood@nuformix.com | +44 (0)1223 627222 |
| Allenby Capital Limited<br><br>Tim Sohal / Matt Butlin (Sales and Corporate Broking)<br><br>Nick Athanas (Corporate Finance) | +44 (0)203 328 5656 |

About Nuformix

Nuformix is a pharmaceutical development company with a current focus in fibrosis and oncology. It is focused on unlocking the therapeutic potential and value of known drugs by repurposing them and developing them into novel medicines and in doing so creating additional commercial opportunities. The model of repurposing is enabled by Nuformix's expertise in the discovery of new forms of known drugs that allow Nuformix to file patent applications and get patent protection for its assets.

Nuformix plc shares are traded on the London Stock Exchange's Official List under the ticker: NFX. For more information, please visit [www.nuformix.com](http://www.nuformix.com/).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com/).  

  

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](https://www.lseg.com/privacy-and-cookie-policy).

END

BOATLMBTMTJMTJB